A £600 million tranche of government funding for a key part of the UK's life sciences strategy – expanding the country's ...
AbbVie's antibody-drug conjugate (ADC) Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, with hundreds of women every year expected to be eligible for ...
Gedatolisib is a PAM pathway inhibitor – combining PI3K and mTOR inhibition in one molecule – and in the VIKTORIA-1 trial was ...
Shares in French biotech Abivax tumbled more than 30% today, after it announced phase 3 data with ulcerative colitis (UC) ...
The Coalition for Epidemic Preparedness Innovations (CEPI) has made $60 million available for clinical trials of vaccines for ...
In the latest part of its plan to cut barriers to cell and gene therapy (CGT) development, the FDA has published draft ...
While still in the early stages of development, in vivo CAR-T therapies have generated excitement about their potential as ...
The SUPPORT+ mobile app, developed by researchers led by Dr Wing-Lok Chan at Hong Kong University, delivers weekly reminders ...
Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...
A three-drug regimen incorporating AstraZeneca's immune checkpoint inhibitors Imfinzi and Imjudo has reduced the risk of ...
AstraZeneca has presented new data from the SERENA-6 trial of camizestrant in advanced breast cancer that it hopes will ...
In AL amyloidosis, abnormal plasma cells in the bone marrow produce misfolded proteins that clump together clump together ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results